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Human chymotrypsin C (CTRC) is a pancreatic protease that
participates in the regulation of intestinal digestive enzyme
activity. Other chymotrypsins and elastases are inactive on the
regulatory sites cleaved by CTRC, suggesting that CTRC recog-
nizes unique sequence patterns. To characterize the molecular
determinants underlying CTRC specificity, we selected high
affinity substrate-like small protein inhibitors against CTRC
from a phage library displaying variants of SGPI-2, a natural
chymotrypsin inhibitor from Schistocerca gregaria. On the basis
of the sequence pattern selected, we designed eight inhibitor
variants in which amino acid residues in the reactive loop at P1
(Met or Leu), P2 (Leu or Asp), and P4 (Glu, Asp, or Ala) were
varied. Binding experiments with CTRC revealed that (i) inhib-
itors with Leu at P1 bind 10-fold stronger than those with P1
Met; (ii) Asp at P2 (versus Leu) decreases affinity but increases
selectivity, and (iii) Glu or Asp at P4 (versusAla) increase affin-
ity 10-fold. The highest affinity SGPI-2 variant (KD 20 pM)
bound to CTRC 575-fold tighter than the parent molecule. The
most selective inhibitor variant exhibited a KD of 110 pM and a
selectivity ranging from 225- to 112,664-fold against other
human chymotrypsins and elastases. Homology modeling and
mutagenesis identified a cluster of basic amino acid residues
(Lys51, Arg56, and Arg80) on the surface of human CTRC that
interact with the P4 acidic residue of the inhibitor. The acidic
preferenceofCTRCatP4 is unique amongpancreatic proteases
and might contribute to the high specificity of CTRC-mediated
digestive enzyme regulation.
Digestion of dietary proteins in the small intestine is cata-
lyzed by proteases secreted from the pancreas. These proteases
are produced as inactive proenzymes (zymogens) and their
activation is spatially restricted to the duodenum and proceeds
in a cascade-like manner. The membrane-localized serine pro-
tease enteropeptidase (enterokinase) activates trypsinogens to
active trypsins, which, in turn, activate all other proteolytic
proenzymes; in the human these include chymotrypsinogens
B1, B2, C, and L1, proelastases 2A, 3A, and 3B, and procarboxy-
peptidases A1, A2, and B1. This classic textbook paradigm of
digestive enzyme activation has been recently revised by the
discovery of interactions between digestive proteases that can
modulate the ultimate levels of active enzymes. In this regard,
we demonstrated that human chymotrypsin C (CTRC)4 regu-
lates activation and degradation of human cationic trypsinogen
and trypsin (1, 2). CTRC facilitates trypsin-mediated activation
(autoactivation) of cationic trypsinogen by processing the tryp-
sinogen activation peptide, at the Phe18–Asp19 peptide bond, to
a shorter form that ismore readily cleaved by trypsin (1).Muta-
tion A16V in the trypsinogen activation peptide stimulates
CTRC-mediated processing and subjects with this mutation
are at increased risk of developing chronic pancreatitis (1, 3).
CTRC can also promote degradation of human cationic tryp-
sinogen and trypsin by cleaving the conserved Leu81–Glu82
peptide bond in the calcium binding loop, when the calcium
concentration is low and the binding loop is unoccupied (2).
The combination of this cleavage and an autolytic cleavage at
Arg122 results in the degradation and complete inactivation of
cationic trypsin. Hereditary pancreatitis-associated mutation
R122H eliminates the Arg122 autolysis site in cationic trypsin-
(ogen) and prevents CTRC-induced degradation, suggesting
that trypsin(ogen) degradation is an important defensivemech-
anism in the pancreas (2, 4). Consistent with this notion,
genetic association studies identified loss-of-function muta-
tions in CTRC as risk factors for chronic pancreatitis (5, 6).
More recently, we found that humanCTRC is a physiological
co-activator of human procarboxypeptidases A1 and A2 (pro-
CPA1 and pro-CPA2) (7). Digestive carboxypeptidases are
secreted by the pancreas as inactive proenzymes containing a
94–96-amino acid long propeptide that acts as a strong inhib-
itor of the enzymes thereby maintaining their zymogen state.
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Activation of procarboxypeptidases is initiated by trypsin-me-
diated proteolytic cleavages at the C-terminal end of the pro-
peptides. However, the trypsin-processed propeptides are still
inhibitory and subsequent cleavages by CTRC are required for
full activation of pro-CPA1 and pro-CPA2. CTRC cleaves the
propeptides at multiple sites, but the critical step for activation
appears to be cleavage of the conserved Leu96–Leu97 peptide
bond in both proenzymes (7).
The CTRC-catalyzed regulatory functions are highly specific
as other human pancreatic chymotrypsins and elastases exhibit
no such activity (1, 2, 7). This may be partly due to the primary
(P1) specificity of CTRC, which is chymotrypsin-like, but
CTRC exhibits higher activity on leucyl peptide bonds than
chymotrypsin A or B (8–10). However, other determinants
may be also important, as suggested by the preponderance of
acidic amino acid residues on the prime side of the CTRC-
specific regulatory cleavage sites (Table 1). Despite the similar-
ities in these sequences, the number of CTRC-specific cleavage
sites identified hitherto is too few to determine the inherent
binding site preference of CTRC. Functional importance of
individual amino acid residues within a linear binding epitope
of substrates can be assessed throughmutational replacements,
but a complete analysis would require an impractically large
number of mutants. If recognition relies on cooperating sub-
strate positions, the combination of mutants required for full
coverage of all possible sequence variations would reach astro-
nomical numbers. Directed evolution combines combinatorial
mutagenesis with functional selection and provides a straight-
forward solution to these problems (11). Substrate-like canon-
ical inhibitors mimic natural peptide substrates in their inter-
actions with proteases (12, 13). In the present study we utilized
phage display, possibly the most robust directed evolution
approach, to define the substrate specificity of human CTRC.
We fully randomized six protease binding loop positions in the
chymotrypsin inhibitor SGPI-2, displayed the library on M13
phage, and selected tight binding variants against CTRC. Based
on the selected sequence pattern, eight SGPI-2 variants desig-
nated C1 through C8 were produced and characterized. The
results suggest that a unique electrostatic interaction between a
cluster of basic residues onCTRC and the P4 acidic amino acid
residue of CTRC substrates is an important determinant of
CTRC specificity.
EXPERIMENTAL PROCEDURES
Nomenclature—Amino acid residues in human pancreatic
proteases were numbered starting with the initiator methio-
nine of the primary translation product; according to the rec-
ommendations of the Human Genome Variation Society.
Where indicated, the traditional crystallographic numbering
systembased on the bovine chymotrypsinA sequencewas used.
Amino acids in SGPI-2 were numbered starting from the first
residue in the mature inhibitor (Glu1).
SGPI Library Construction—Library construction was based
on the Tag-wtSGPI-2-pGP8 phagemid vector (14), which mono-
valently displays SGPI-2 on the p8 coat protein of the M13
phage. The library was produced in two successive Kunkel
mutagenesis (15) steps to avoid wild-type SGPI-2 contamina-
tion. First, the Tag-SGPI-2-pGP8-STOP vector was con-
structed in which all codons to be randomized were replaced
with stop codons using the following primer (where the stop
codons are underlined): 5-GC GGT AGC GAT GGC AAA
AGC GCG TAA TGC TAA TAA TAA TAA TGC TAA CAG
GGT ACC GGT GGA GG-3. In the second step, the resulting
Tag-wtSGPI-2-pGP8-STOP vector was used as template in a
combinatorial Kunkel mutagenesis step modified slightly for
large scale generation of diverse libraries (16). Stop codonswere
replaced with amino acid coding codons randomized using
NNK degeneracy, where N denotes nucleotides A, C, G, or T,
and K stands for G or T. NNK codons represent a set of 32
codons covering all 20 amino acid residues. The following
mutagenesis primer was used (where NNK codons are under-
lined): 5-GC GGT AGC GAT GGC AAA AGC GCG NNK
TGCNNKNNKNNKNNKTGCNNKCAGGGTACCGGT
GGA GG-3. The Tag-SGPI-2-pGP8-Lib library construct is
illustrated under supplemental Fig. S1. The phagemid library
was electroporated into Escherichia coli SS320 cells to generate
phage libraries as described (16).
Selection of Inhibitor Phages on CTRC—Human CTRC was
immobilized in 12 wells of an Immobilizer Amino plate (Nunc
International) using 5 g of CTRC/well in 100 l of 10 mM
Hepes buffer (pH 7.8) containing 0.15 MNaCl, for 3 h. Thewells
were rinsed with phosphate-buffered saline (PBS, pH 7.2) and
blocked with 200 l of bovine serum albumin (BSA, 5 mg/ml
dissolved in PBS) for 1 h. A control plate was treated with BSA
only without adding CTRC. The wells were rinsed four times
with PBS containing 0.05% Tween 20 (final concentration).
Phages (100l,5 1011 phage particles per well) were added
to the wells in PBS/BSA solution containing 0.05% Tween 20
and incubated for 2 h. Plates were rinsed 12 times with PBS
containing 0.05% Tween 20 and bound phages were eluted at
pH 1.0 with 100 mM HCl (100 l/well) for 1 min. The eluted
phage solution was neutralized by adding 15% volume of 1 M
Tris base solution and phages were amplified in E. coli XL1-
Blue. Three selection and amplification cycles were performed
as described (16). After the second and third cycles, the inhib-
itor-phage titers eluted from target and control plates were
determined and enrichment values were calculated to charac-
terize the efficiency of the selection process. The enrichment
TABLE 1
Sequence context of CTRC-specific regulatory cleavage sites in human cationic trypsinogen and procarboxypeptidases A1 and A2
CTRC target proenzymes CTRC cleavage sites
P3 P2 P1 P1 P2 P3 P4
Cationic trypsinogen activation peptide Ala16-Pro17-Phe18-Asp19-Asp20-Asp21-Asp22-
Cationic trypsinogen calcium binding loop -Glu79-Val80-Leu81-Glu82-Gly83-Asn84-Glu85-
Procarboxypeptidase A1 propeptide -Gln94-Ser95-Leu96-Leu97-Asp98-Glu99-Glu100-
Procarboxypeptidase A2 propeptide -Gln94-Val95-Leu96-Leu97-Asp98-Lys99-Glu100-
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was 40- and 900-fold after the second and third cycles,
respectively.
Phage ELISA of Selected LibraryMembers—Individual clones
from the third selection cycle were tested in phage ELISA per-
formed as described (16). Clones producing ELISA signals
3-fold higher on CTRC containing plates than on albumin-
coated control plates were selected for DNA sequencing.
Sequence Analysis—DNA sequences coding for SGPI-2 vari-
ants were PCR amplified from the selected library members
with the following primers annealing to invariant vector
sequences; forward primer, pTacUp35T7, 5-CGA AAT TAA
TAC GAC TCA CTA TAG GGC TAT AGG GTC TGG ATA
ATG TTT TTT GCG CC-3 and reverse primer, pVIII-rev,
5-GTTATGCTAGTTATTGCTCAGCGGCTTGCTTTC
GAG GTG AAT TTC-3. The forward PCR primer was
designed to contain the sequence of the T7 promoter sequenc-
ing primer: 5-CGA AAT TAA TAC GAC TCA CTA TAG
GG-3, which was then used for the sequencing reactions.
Clones with unique DNA sequences were aligned and amino
acid frequencies at the randomized positions were determined.
These frequencies were normalized to the expected codon fre-
quencies in theNNKdegenerated set, to eliminate the effects of
codonbias. For logo representation of the normalized results an
input sequence dataset containing 100 sequences was gener-
ated representing the normalized amino acid frequencies at
each randomized position. Sequence logos were generated by
the web-based application WebLogo (17).
Expression and Purification of SGPI-2 Variants—Recombi-
nant SGPI-2 variants were expressed into the periplasm of
E. coli as maltose binding protein fusions (18). PCR amplified
genes of SGPI-2 variants were subcloned into the pMal-p2G
vector (New England Biolabs) using EcoRI and HindIII restric-
tion sites. The following universal 5 primer was used, which
contained an EcoRI site (underlined), a TEV protease cleavage
site coding segment (bold), a Ser-Gly-Ser linker coding segment
(italic), and the first six codons of the SGPI-2 gene (italic and
underlined): 5-A CTG GAA TTC GAA AAC CTG TAT TTT
CAGGGATCCGGCGAGGTGACCTGCGAACCG-3. Each
3 primer contained a variant-specific segment and a common
segment with two consecutive stop codons and a HindIII
restriction site. The expression plasmid is illustrated under sup-
plemental Fig. S1. E. coli BL21 StarTM (Invitrogen) cells trans-
formed with the appropriate expression vector were grown in 1
liter of LB/ampicillin medium at 37 °C until the optical density
of the culture measured at 600 nm reached 0.5 and expression
was induced overnight with 0.3mM isopropyl 1-thio--D-galac-
topyranoside (final concentration). Cells were harvested by
centrifugation (10min, 6,000 g at 4 °C), resuspended in 80ml
of ice-cold 1 mM MgCl2 solution, and kept frozen at 20 °C
overnight. The next morning the suspension was thawed and
cells were removed by centrifugation (10 min, 15,000  g at
4 °C). The supernatant containing the periplasmic fraction was
treated with 20 units/ml of BenzonaseTM (Novagen) overnight
at room temperature to eliminate nucleic acid contamination.
Ammonium sulfate was added to 90% saturation and precipi-
tated proteins were recovered by centrifugation (10 min,
15,000 g at 4 °C). Proteins were suspended in 70ml of 2.5mM
HCl and dialyzed against the same solution twice for 2 h each.
Precipitated proteins were removed by centrifugation (10 min,
15,000 g at 4 °C). The pH of the supernatant was adjusted to
8.0 by adding Tris-HCl buffer to a 50 mM final concentration
and themaltose binding protein-SGPI-2 fusion was purified on
a 5-ml HiTrap Q HP (GE Healthcare Life Sciences) ion-ex-
change columnusing the samebuffer and a linear 0–0.5MNaCl
gradient on a GE Healthcare FPLC system. The fusion protein
eluted at 0.25 M NaCl concentration. Two or three peak frac-
tions (1 ml each) were pooled; and AcTEVTM protease (10,000
units/ml containing 5mMDTT; Invitrogen)was added to attain
a 100 units/ml protease concentration and 50 M final DTT
concentration. The sample was incubated overnight at room
temperature and completeness of the cleavage reaction was
verified by SDS-PAGE and Coomassie Blue staining. The sam-
ple was then loaded on a column containing immobilized amy-
lose (New England Biolabs) to capture the released maltose
binding protein tag. The flow-through containing the SGPI-2
variant was filtered through a 22-m membrane and loaded
onto a Jupiter C4 300A (250 10mm) RPHPLC column (Phe-
nomenex). Solvent A was 0.1% trifluoroacetic acid (TFA) and
solvent B was acetonitrile with 0.08% TFA. SGPI-2 variants
eluted as symmetrical peaks and were found to be homogene-
ous and of correct size by mass spectrometry on an HP1100
HPLC-ESI-MS system (Agilent Technologies). Purified SGPI-2
variants were lyophilized and dissolved in 10 mM Tris-HCl (pH
8.0) before use.
Expression and Purification of Human Pancreatic Proteases—
Human cationic trypsin (PRSS1), human anionic trypsin
(PRSS2), chymotrypsins CTRB1, CTRB2, CTRC, CTRL1, and
elastases ELA2A, ELA3A, and ELA3B were expressed as inac-
tive precursors (zymogens) either in E. coli BL21(DE3) or in
HEK 293T cells and purified as previously described (Ref. 7 and
references therein). CTRB1, CTRB2, CTRC, CTRL1, and
ELA3B zymogens were activated with immobilized bovine
trypsin (Pierce; Thermo Fisher Scientific, Rockford, IL) and the
trypsin-containing beads were removed by centrifugation.
ELA3A and ELA2A precursors were activated with human cat-
ionic trypsin and anionic trypsin, respectively, and trypsin was
removed by passing the activation mixtures through a 1-ml
benzamidine column (GE Healthcare). Active proteases were
stored in 0.1 M Tris-HCl (pH 8.0) and 0.05% Tween 20 (final
concentrations) at 4 °C. Protease concentrations were verified
before each experiment either by active site titration or activity
assay.
Concentration Determinations—Bovine trypsin (Worthing-
ton Biochemicals) was dissolved in 0.1 M Tris-HCl (pH 8.0), 1
mM CaCl2 at a concentratin of50 M and active site-titrated
using p-nitrophenyl p-guanidinobenzoate, as described (19).
The pan-protease inhibitor ecotin (20, 21)was overexpressed in
E. coli BL21(DE3) and purified from the periplasm as described
previously (22). The concentration of ecotin was determined by
titration against the active site-titrated bovine trypsin. This
ecotin batch served then as a universal titrant for all human
pancreatic proteases studied. We have determined the equilib-
rium dissociation constants (KD) of ecotin with human pancre-
atic proteases (supplemental Table S1) and titrations were per-
formed using protease concentrations at least 2 orders of
magnitude above the KD values, with the exception of ELA3A,
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which was titrated at a concentration5 times above KD. The
concentration of SGPI-2 and its variants was determined by titra-
tion against CTRC. Immediately before the binding experiments,
all tight-binding protease-inhibitor pairs were re-titrated against
each other to ensure “self-consistent” concentrations.
Equilibrium Binding Assays—Binding of SGPI-2 variants to
human chymotrypsins and elastases was characterized by
determining the KD value of the reaction in equilibrium,
according to the method of the Laskowski laboratory (23). A
fixed protease concentration (between 0.5 and 10 nM) was
reacted with increasing concentrations of the inhibitor, and the
free (unbound) protease concentration was determined by enzy-
matic assays using appropriate fluorogenic or chromogenic pep-
tide substrates (listed in supplemental Table S2). Inhibitors and
proteases were incubated in 0.1 MTris-HCl (pH 8.0), 1mMCaCl2,
and 0.05% Tween 20 (final concentrations) for 1 h at 22 °C in
microtiter plates in a 100-l final volume and substrates were
given in a 5-l volume so as not to perturb the equilibrium. The
free protease concentration was plotted as a function of the
total inhibitor concentration and the experimental points
were fitted with the following equation:
y  E  (E  x  K-sqrt((E  x  K)2  4Ex))/2, where the
independent variable x represents the total inhibitor concen-
tration, the dependent variable y is the free protease concentra-
tion in equilibrium, K is KD, and E designates the total protease
concentration.
Structural Modeling of the CTRC-C6 Complex—Several
homology models of human CTRC were constructed using the
SWISS-MODELWorkspace (24) using porcine elastase bound
to Ascaris chymotrypsin/elastase inhibitor (PDB code 1EAI
chain A; 52% identity) (25), bovine chymotrypsin bound to
pacifastin inhibitor PMP-C (PDBcode 1GL1 chainA, 36% iden-
tity) (26), and bovine chymotrypsinogen C (PDB code 1PYT
chain D; 80% identity) (27) as templates. Because substantial
conformational changes throughout the substrate binding cleft
take place upon serine protease activation, we chose the model
based on porcine elastase as the best approximation of the active
CTRC structure. The three homology models were quite similar
overall but differed considerably over a 5-residue loop (residues
238–242 in the human CTRC sequence) that in the elastase-
based model clashed with the anticipated orientation of the C6
inhibitor; these residues were replaced with the corresponding
residues from the homology model based on bovine chymot-
rypsinogen C. A homology model of the C6 inhibitor was con-
structed in the SWISS-MODEL Workspace using as a template
PMP-C(PDBcode1GL1chain I;76%identity) (26).Thehomology
models of humanCTRC and inhibitor C6 were first dockedman-
uallybasedontheorientationofPMP-Candchymotrypsin inPDB
code 1GL1, and then a local docking search with energy minimi-
zation of side chain rotamers at the intermolecular interface was
performed using the RosettaDock server (28).
RESULTS
Analysis of CTRC Specificity through Phage Display Selection
of Substrate-like SGPI-2 Inhibitor Variants—To identify deter-
minants of CTRC substrate specificity, we utilized a phage dis-
play approach, in which a library of inhibitor variants was con-
structed and phages carrying tight-binding inhibitors were
selected. We used SGPI-2, a chymotrypsin inhibitor from the
desert locust Schistocerca gregaria as our scaffold for inhibitor
selection (Fig. 1A) (29–32). The 35-amino acid SGPI-2, which
belongs to the pacifastin inhibitor family, had already been effi-
ciently displayed on the surface of M13 phage (14). Wild-type
SGPI-2 inhibited human chymotrypsins and elastases with KD
values ranging from 0.2 nM to 2 M, and generally stronger
inhibitionwas apparent for chymotrypsins (Table 2). To display
SGPI-2 on the surface of the M13 phage, it was fused to the N
terminus of the p8 coat protein. Six positions in the reactive
loop of SGPI-2 were fully randomized, which included P4, P2,
FIGURE 1. Phage display-selected S. gregaria chymotrypsin inhibitor
(SGPI-2) variants. A, primary structure of wild-type SGPI-2. The amino acid
positionswithin the reactive loop thatwere randomized in the phage display
library are highlighted as white letters on a black background. The disulfide
bonds are indicated. B, sequence logo representation of the reactive loop of
phage-selected CTRC inhibitors. The logo was generated with the WebLogo
program. The overall height of the stack of symbols indicates the sequence
conservation at that position, whereas the height of symbols within the stack
indicates the relative frequency of each amino acid. The colors indicate the
chemical properties of the amino acid side chains; aliphatic is green, aromatic
is orange, acidic is red, basic is dark blue, and polar with no charge is light blue.
Note that the Cys residues shown in gray at the P3 and P3 positionswere not
randomized. Their symbol height represents themaximal height correspond-
ing to a completely conserved residue. C, reactive loop sequences of eight
SGPI-2 variants designed to test the significance of the P1 (Met or Leu), P2
(Leu or Asp), and P4 (Glu, Asp, or Ala) positions in binding affinity. The corre-
sponding P4-P4 segment in wild-type SGPI-2 is indicated in panel A. These
eight inhibitors aswell aswild-type SGPI-2were expressed, purified, and their
inhibitory activity was tested on human pancreatic chymotrypsins and elas-
tases. See text for further details.
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P1, P1, P2, and P4 (Fig. 1A, supplemental Fig. S1A). The P3
and P3 Cys residues are structurally indispensable and these
were therefore conserved. Selection of tight-binding clones was
performed against immobilized human CTRC. Three selection
cycles were performed and tight binding inhibitor containing
phages were verified by ELISA and subjected to DNA
sequencing.
Selected Tight Binding SGPI-2 Variants Reveal Unexpected
Acidic Residues at P4 Position of the Reactive Loop—From the
sequence analysis of 32 inhibitor phage clones, 22 were unique
at the DNA level, indicating that these were the results of
independent selection events. The reactive loop sequence of the
individual clones is listed under supplemental Table S3. To
define the characteristic sequence pattern for CTRC inhibition,
we created a codon-normalized sequence logo from the indi-
vidual sequences, in which symbol height was used to represent
sequence conservation at positions P4 through P4 (Fig. 1B).
The normalized sequence pattern indicated selection of Met
and Leu amino acid residues at the P1 position, which corre-
sponded to the expected P1 specificity of CTRC. The P2 posi-
tion showed a strong consensus for Thr; however, this most
likely reflects stabilizing interactions between the reactive loop
and the inhibitor core (see “Discussion”). A slight predomi-
nance of Ala and Gly were detected at the P4 position, which
showed the lowest degree of sequence conservation of all posi-
tions randomized. On the prime side of the reactive loop, both
the P1 and P2 positions showed a clear preference for hydro-
phobic side chains, Met and Leu, respectively. Interestingly,
acidic amino acid residuesAsp andGluwere also selected at the
P2 position, althoughwith a lower frequency than Leu. Finally,
the most striking feature of the sequence logo was the almost
exclusive presence of acidic Glu andAsp amino acid residues at
position P4. Taken together, the phage display results suggest
that the sequence pattern of the reactive loop of SGPI-2 vari-
ants that most likely bind to CTRC with high affinity is
Xaa-Cys-Thr-Met/Leu-Met-Leu-Cys-Glu/Asp.
Phage Display-evolved CTRC Inhibitors Exhibit Improved
Binding Affinity Relative to Parent SGPI-2—On the basis of the
reactive loop sequence pattern derived from tight binding
inhibitor-phage clones, we have designed six SGPI-2 inhibitor
variants, in which positions P1 (Met or Leu), P2 (Leu or Asp),
andP4 (Glu orAsp)were varied,whereas positions P4 (Ala), P2
(Thr), and P1 (Met) were fixed (see Fig. 1C). In addition, to test
the contribution of the P4 acidic side chain to binding affinity,
we designed two inhibitors with P4 Ala (Fig. 1C). The eight
inhibitors were expressed in E. coli, purified to homogeneity,
and their binding to CTRC was characterized by determining
the equilibrium dissociation constants (KD). Representative
binding experiments are shown in Fig. 2A and theKD values for
CTRC are demonstrated by Fig. 2B. KD values for the eight
inhibitors were also measured with the full complement of
human pancreatic chymotrypsins and elastases (Table 2). To
better illustrate the selectivity of the inhibitors, KD values were
also expressed after normalization to the CTRC KD, which was
set to equal one (Table 2). Full characterization of wild-type
SGPI-2 and phage display-selected variants required 88 inde-
pendent KD determinations in the present work.
As expected, compared with the inhibition of CTRC by the
parent molecule SGPI-2 (KD 11.5 nM, see Table 2), all eight
SGPI-2 variants exhibited significantly higher binding affini-
ties, with KD values ranging from 0.02 to 0.9 nM, which corre-
sponded to 13- to 575-fold improvement. Interestingly, relative
to inhibition by the parent molecule SGPI-2, chymotrypsins
CTRB1, CTRB2, and CTRL1 were inhibited by the CTRC-se-
lected inhibitors less strongly, whereas inhibition of elastases
ELA2A, ELA3A, and ELA3B showed a tendency for improve-
ment.With respect to binding affinity, the best CTRC inhibitor
was C4 (KD 20 pM), which also exhibited good selectivity (range
46–12,650-fold) against other pancreatic chymotrypsins and
elastases. With respect to selectivity, the best inhibitor was C6,
with a KD value of 110 pM and a selectivity that ranged from
225- to 112,664-fold (Table 2).
Leu at P1 Affords Tighter Binding Than Met—According to
the sequence logo,Met or Leu at P1 should result in comparable
inhibition of CTRC. Surprisingly, however, when purified
inhibitors with P1 Leu or Met were compared, inhibitors with
Leu consistently showed stronger inhibition of CTRC by about
an order of magnitude (average 12-fold; range 8–16-fold) (cf.
C1 with C4, C2 with C5, and C3 with C6, in Figs. 2B and 3 and
Table 2). CTRB2 exhibited a similarly strong P1 preference for
Leu and the same general trendwas apparent for other chymot-
rypsins and elastases, although the magnitude of the difference
between inhibition by Leu and Met P1 was typically smaller
than seenwithCTRC (Fig. 3, Table 2). Consequently, relative to
Met, the Leu P1 not only increased affinity for CTRC but also
increased the selectivity of the CTRC inhibitors against other
chymotrypsins and elastases by an average of 4-fold (range
1–12-fold) (Table 2). Interestingly, the presence of Asp (versus
Leu) at the P2 position mitigated the Leu P1 preference of
CTRC and CTRB2 by 2- and 5-fold, respectively (cf. Fig. 3, C
with A and B).
TABLE 2
Inhibition of humanpancreatic chymotrypsins and elastases by S. gre-
garia chymotrypsin inhibitor (SGPI-2) and phage display-selected
SGPI-2 variants
Equilibrium dissociation constants (KD) shown in bold were determined as
described under “Experimental Procedures” and expressed in nanomolar units of
concentration. To quantify the selectivity of the inhibitors, KD values were normal-
ized to the CTRCKD, which was set to equal one. These selectivity values are shown
in italics below their corresponding KD. Values above one were rounded to the
nearest whole number. See Fig. 1 for the primary structure of the inhibitors used.
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Acidic Amino Acid Residues at P4Markedly Increase Inhib-
itor Affinity to CTRC—The essentially exclusive selection of
Glu and Asp residues at the P4 position in tight binding
inhibitor-phage clones suggested that acidic residues are
important determinants of inhibitor and substrate binding
to CTRC. In agreement with these expectations, the equilib-
rium binding experiments demonstrated that CTRC binds
inhibitors with P4 Glu about an order of magnitude stron-
ger (average 13-fold, range 8–18-fold) than inhibitors with
P4 Ala (cf. C4 with C7 and C6 with C8 in Fig. 4 and Table 2).
In contrast, other chymotrypsins generally bound inhibitors
with P4 Glu more weakly than those with P4 Ala, whereas
in the case of elastases the Glu versusAla exchange at P4 had
no effect on inhibitor binding (Fig. 4). Binding affinities of
inhibitors with P4 Glu or Asp were comparable (cf. inhibi-
tors C1 with C2 and C4 with C5 in Table 2), although inhib-
itors with P4 Asp showed a tendency toward slightly weaker
binding, but the difference was within experimental error.
Interestingly, the P2 position had a small, but measurable
influence on the effect of the P4 position on chymotrypsins
(cf. C4 with C6 and C7 with C8 in Fig. 4). The P2Asp (versus
Leu) reduced the affinity increasing effect of the P4 Glu
(versus Ala) toward CTRC by about 2-fold, whereas it
enhanced the unfavorable effect of the P4 Glu on binding
affinity toward CTRB1 and CTRB2 by about 3-fold.
Because the positive effect of the P4Glu/Asp on inhibitor
binding is highly specific for CTRC, this residue is also the
most important determinant of inhibitor selectivity against
other pancreatic chymotrypsins and elastases. CTRC inhib-
FIGURE 2. Inhibition of human CTRC by phage display-selected SGPI-2
variants. A, representative inhibitor-binding experiments with the C4 and
C6 SGPI-2 variants using 0.5 nM CTRC concentration. B, equilibrium disso-
ciation constant (KD) values determined for eight CTRC-specific inhi-
bitors. Measurements were carried out as described under “Experimental
Procedures.”
FIGURE 3. The effect of the P1 residue (Leu or Met) on the inhibition of
human pancreatic chymotrypsins and elastases by phage display-se-
lected SGPI-2 variants. Pairwise comparison of relative KD values (P1 Leu set
to equal one) is shown for inhibitor pairs differing only at the P1 position. The
amino acid residues found at P2 and P4 are also indicated.
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itors with P4 Glu (versus Ala) are on average 10-fold (range
6–13-fold) more selective against elastases and on average
55-fold (range 12–100-fold) more selective against other
chymotrypsins (cf. C4 with C7 and C6 with C8 in Table 2).
The P2 Asp Decreases Binding Affinity but Increases Selec-
tivity of SGPI-2 Variants—The phage-selected sequence pat-
tern suggests that the optimal residue at P2 for CTRC bind-
ing is Leu. However, contrary to our expectations, acidic
residues (Asp or Glu) were also selected at this position. This
observation suggested that acidic residues at P2 offer a non-
homologous alternative solution for binding to the S2 site of
CTRC without significant loss of affinity. Binding experi-
ments with purified inhibitors confirmed that, relative to a
P2 Leu, the presence of P2 Asp caused only an average of
3.6-fold (range 2.5–5.5-fold) decrease in binding affinity
toward CTRC (cf. C1 with C3, C4 with C6 and C7 with C8 in
Fig. 5 and Table 2). Binding to CTRB1 and CTRB2 was sim-
ilarly affected. In contrast, the P2 Asp caused a much more
significant (on average 25-fold, range 5–49-fold) decrease
in the inhibition of elastases and CTRL1 (Fig. 5). Because of
this difference, the P2 Asp appreciably (on average7-fold,
range 2–17-fold) increased the selectivity of the CTRC
inhibitors against elastases and CTRL1 (Table 2).
Modeling Suggests That a Cluster of Positively Charged CTRC
Residues Interact with the Acidic P4 Residue of the Inhibitor—
The most intriguing finding from the phage display selection
was the preference of CTRC for acidic residues at the P4 posi-
tion; this preference is unique among pancreatic proteases. To
gain insight into potential structural determinants of this
aspect of CTRC specificity, we generated homology models of
CTRC (modeled on porcine elastase and bovine CTRC zymo-
gen) and the C6 inhibitor (modeled on PMP-C, a homologous
inhibitor from Locusta migratoria). We docked the CTRC-C6
model complex using a local docking search with energy mini-
mization of side chain rotamers at the intermolecular interface.
The resultant C6 inhibitor orientation and placement of resi-
dues occupying the P4-P4 positions closely mimic those
observed in the crystal structure of the complex formed by
bovine chymotrypsin with PMP-C (PDB code 1GL1) (26), lend-
ing support to the validity of our model. In examining the envi-
ronment surrounding the P4 Glu residue in the model, we
observed a cluster of basic residues that apparently interact
with and stabilize the negative charge borne by this residue (Fig.
6). In the model, the side chain carboxylate oxygens of the P4
Glu form salt bridges with Lys51 and Arg80, with distances of
about 2.6 and 3.4 Å, respectively, and the backbone carbonyl
oxygen of the P4 Glu accepts an H-bond from nearby Arg56.
We hypothesize that these interactions contribute to the pref-
erence of CTRC for acidic residues at the P4 position.
Beyond the P4 position, we examined the CTRC-C6 model
for insights into binding specificity at additional prime side sub-
sites of CTRC,which differ from those of typical chymotrypsins
and elastases. At the P1 position, mammalian chymotrypsins
typically show a preference for basic residues Arg and Lys,
which has been attributed to interactions with conserved acidic
residues Asp35 and Asp64 (chymotrypsin numbering) (33). In
human CTRC, each of these Asp residues is substituted with
the bulkier, uncharged Tyr, potentially explaining a preference
for the shorter, hydrophobic side chain of Met at the P1 posi-
tion. At the P2 position, human CTRC proved to be unexpect-
edly permissive of acidic side chains Asp and Glu; this may be
due to the positioning of the bound P2 residue between the
basic side chains of Arg56 (distance5 Å) and Arg162 (distance
6 Å). Although these distances may not suggest particularly
close ion pair contacts, it has been well documented that elec-
trostatic interactions in the range of 4–7 Å can contribute sub-
stantially to the energetics of protein-protein association,
depending upon the local environment (34).
Mutational Analysis of CTRC Residues Lys51, Arg56, and
Arg80 Supports Their Interaction with the Acidic P4 Residue of
the Inhibitor—To test the predictions of our CTRCmodel with
respect to the binding of the P4 Glu amino acid residue of
inhibitors, wemutated Lys51 andArg56 toAla, individually (sin-
gle mutants K51A and R56A) and in combination (double
mutant K51A,R56A). We also mutated Arg80 to Leu (mutant
R80L). Leu was used at this position because in most mamma-
lianCTRCmoleculesArg80 is not conserved andLeu is found in
its place. Finally, to test the effect of an unfavorable negative
charge within this basic amino acid cluster, Arg56 was changed
to Glu (mutant R56E). The CTRCmutants were expressed and
purified and kinetic parameters were determined on the pep-
FIGURE 4. The effect of the P4 residue (Glu or Ala) on the inhibition of
human pancreatic chymotrypsins and elastases by SGPI-2 variants. Pair-
wise comparison of relative KD values (P4 Glu set to equal one) is shown for
inhibitor pairs differing only at the P4 position. The amino acid residues
found at P1 and P2 are also indicated.
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tide substrate Suc-Ala-Ala-Pro-Phe-p-nitroanilide. As shown
under supplemental Table S4, the kcat, Km, and kcat/Km values
for the six mutants were comparable with those of wild-type
CTRC, indicating that the mutations did not perturb the cata-
lytic machinery of CTRC to a significant extent. Binding of the
wild-type SGPI-2 inhibitor by the CTRC mutants was slightly
improved (single mutants K51A and R56A and double mutant
K51A,R56A) or unchanged (mutant R56E), with the excep-
tion of the R80Lmutant, which bound SGPI-2 almost 10-fold
stronger than wild-type CTRC (supplemental Table S5).
This latter effect is probably due to the elimination of a
repulsive interaction between Arg80 on CTRC and the P1
Lys residue in SGPI-2 (not shown).
To determine whether the threemutated basic residues con-
tribute to binding the P4 Glu of CTRC inhibitors, we com-
pared binding of two inhibitor pairs (C4–C7 and C6–C8) dif-
fering only in the P4 position (Glu versusAla). Table 3 lists the
KD values measured. The single neutral mutations (K51A,
R56A, and R80L) in CTRC decreased binding affinity to inhib-
itors with P4Glu by an average of 6-fold (range 4–9-fold), and
this effect was additive in the double mutant K51A,R56A,
which caused an average 31-fold (range 21–40-fold) decrease.
Binding of these CTRCmutants to inhibitors carrying a P4Ala
was only slightly weakened (on average 1.7-fold, range 0.4–4-
fold), and in some cases the mutations actually improved affin-
ity (R80L with C7 and C8, and K51A,R56A with C7, see Table
3). Similarly, the negative charge of the R65E mutant more sig-
nificantly compromised binding to inhibitors with a P4 Glu
(average 33-fold, range 21–46-fold) than those with Ala (aver-
age 6-fold, range 4–7-fold). To visualize the effects of themuta-
tions on the P4 Glu specificity, the ratio of the KD values for
inhibitors containing Ala versusGlu at P4were graphed. Fig. 7
demonstrates that individual mutations of Lys51 and Arg56
decreased, whereas double mutation of these residues
(K51A,R56A) or mutation of Arg80 alone (R80L) abolished the
P4Glu specificity. Introduction of a negative charge in place of
Arg56 (mutation R56E) also reduced the P4 Glu preference of
CTRC. Taken together, the mutagenesis results are consistent
FIGURE 5. The effect of the P2 residue (Leu or Asp) on the inhibition of
human pancreatic chymotrypsins and elastases by phage display-se-
lectedSGPI-2variants.Pairwise comparisonof relativeKDvalues (P2 Leu set
to equal one) is shown for inhibitor pairs differingonly at the P2position. The
amino acid residues found at P1 and P4 are also indicated.
FIGURE 6. Structural modeling predicts specificity determinants. A, over-
viewofhomologymodelof theCTRC-C6complex. CTRC is surface rendered in
gray, with a cluster of three basic residues surrounding the P4 binding site
highlighted in blue (nitrogens) and yellow (carbons); the inhibitor is shown in
orange.B, enlarged viewof theP4binding site, showing interactions of Lys51,
Arg56, and Arg80 with the P4 Glu residue of the C6 inhibitor.
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with the predictions of the modeling and confirm that Lys51,
Arg56, and Arg80 participate in stabilizing interactions with the
P4 Glu of phage-selected CTRC inhibitors.
DISCUSSION
Recent studies highlighted human CTRC as a unique diges-
tive enzyme with the ability to regulate the activity levels of
other digestive proteases, trypsins, and carboxypeptidases in
particular, through promotion of their activation or degrada-
tion (1, 2, 7). These regulatory functions, reviewed in detail
under the Introduction, are highly specific to CTRC as other
human pancreatic chymotrypsins and elastases exhibit no such
activity. The CTRC specificity is partly explained by the known
affinity of CTRC for leucyl peptide bonds (8–10). However,
taking into account that Leu is themost abundant amino acid in
proteins, other recognition determinants in the regulatory
CTRC cleavage sites should be also relevant. In this respect,
alignment of sequences flanking the regulatory cleavage sites in
human cationic trypsinogen (Phe18-Asp19 and Leu81-Glu82)
and in human pro-CPA1/pro-CPA2 (Leu96–Leu97) reveals a
clustering of acidic amino acid residues on the prime side of the
scissile peptide bonds, from P1 through P4 (Table 1). To
define the cleavage specificity of CTRC and thereby gain fur-
ther insight into its physiological function, in the present study
we utilized a phage display approach to select tight-binding
substrate-like chymotrypsin inhibitor variants. To borrow the
title of a recent comprehensive reviewbyZani andMoreau (36),
“phage display is a powerful tool to engineer protease inhibi-
tors”; either to gather information on protease specificity or to
generate specific reagents for inhibition studies (35). Here, we
used SGPI-2, an arthropod-derived small chymotrypsin inhib-
itor from the pacifastin family (29–32) as a scaffold and fully
randomized six positions in the reactive loop, spanning fromP4
through P4, with the exception of the structurally essential P3
and P3 Cys residues (see Fig. 1).
The results of the phage display selection against CTRC
yielded SGPI-2 variants with a reactive loop sequence pattern
that identified the amino acid preference of CTRC at five of the
six positions randomized, i.e. at P4, P1, P1, P2, and P4. The
sole exception was position P2, where a Thr residue was
selected predominantly. The P2 Thr is a characteristic feature
of many canonical protease inhibitors and it is also strictly con-
served in the pacifastin family (32, 33). Both NMR and crystal
structures demonstrated that in SGPI homologues the P2 Thr
in the reactive loop and Asn15 in a supporting loop participate
in a stabilizing H-bond network (26, 37–45). Consequently,
conservation of the P2Thr uponphage display evolution simply
recapitulates natural evolution and does not represent the
selection of a true protease specificity determinant. From the
five positions allowing insight into CTRC specificity, four (P1,
P1, P2, and P4) demonstrated a clear predilection toward
certain amino acid residues, whereas selection at position P4
was diverse, with only a small preference for small amino acid
residues Ala and Gly. On the basis of the sequence pattern
selected we have designed and expressed eight SGPI-2 variants
and studied their binding to CTRC and a panel of human chy-
motrypsins and elastases. All eight variants showed signifi-
cantly improved binding to CTRC relative to the parent SGPI-2
molecule. The C4 variant with the highest affinity (KD 20 pM)
represented a 575-fold improvement over wild-type SGPI-2.
With respect to the primary (P1) specificity determinant, the
large majority of selected phage clones carried SGPI-2 variants
with Met or Leu residues at this position. These two residues
are characteristically found in the reactive site of naturally
occurring chymotrypsin inhibitors. In a now classic project, the
Laskowski laboratory (46) purified and sequenced ovomucoid
third domains from 153 bird species, and in the P1 position of
the reactive loop found Met and Leu 60 and 66 times, respec-
tively. Nevertheless, when we compared purified SGPI-2 vari-
ants in direct binding experiments, the inhibitors containing a
P1 Leu bound to human CTRC with an order of magnitude
higher affinity than those with P1 Met (see Fig. 3). Thus, Leu is
the preferred amino acid residue at the P1 position for human
CTRC, which is consistent with the known activity of porcine
and bovine CTRC on leucyl peptide bonds (8–10). The compa-
rable selection of phage clones withMet and Leu at P1 suggests
that a binding equilibriumhas not been reached in our selection
experiments. Several phage display studies established that
ratios of normalized amino acid frequencies correlate with
affinity ratios of the corresponding variants (47–50). However,
this correlation applies only when the selection process reaches
binding equilibrium, which for high affinity variants with slow
FIGURE 7. Effect of CTRC mutations on binding to SGPI-2 variants differ-
ing in the P4 position only (Ala versus Glu). Equilibrium dissociation con-
stants (KD) were determined for the C7/C4 and C8/C6 inhibitor pairs, as
described under “Experimental Procedures.” The ratio of the KD values (Ala
over Glu) was plotted. A high ratio signifies preference for Glu-containing
inhibitors, whereas a low ratio indicates loss of P4 specificity. The dotted line
indicates a ratio of 1, with no discrimination between inhibitors containing
Ala or Glu at P4 in their reactive loop.
TABLE 3
Effect ofmutationsof Lys51, Arg56, andArg80 inCTRCon thebindingof
SGPI-2 variants
Equilibrium dissociation constants (KD) were determined as described under
“Experimental Procedures” and expressed in nanomolar units of concentration. See
Fig. 1 for the primary structure of the inhibitors used.
C4 C6 C7 C8
CTRC 0.02 0.11 0.35 0.88
K51A 0.08 0.99 0.51 3.3
R56A 0.13 0.90 0.63 0.89
K51A, R56A 0.42 4.4 0.25 3.6
R80L 0.12 0.69 0.14 0.55
R56E 0.41 5.0 1.4 6.5
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off rates may take longer than an experimentally practical time
frame.
On the prime side of the reactive loop of selected SGPI-2
variants hydrophobic amino acid residues Met and Leu domi-
nated at the P1 and P2 positions, respectively. The P1 pref-
erence of human CTRC resembles that of trypsin rather than
chymotrypsin. Thus, bovine cationic and rat anionic trypsin
prefer Met side chains at P1, whereas bovine and rat chymo-
trypsin prefer positively charged Arg or Lys side chains at this
position (30, 34, 51–54). The characteristic Arg/Lys P1 prefer-
ence of chymotrypsin is attributed to electrostatic interactions
with two negatively charged residues, Asp35 andAsp64 (chymo-
trypsin numbering), which are not conserved in human CTRC
(34). The selection of Leu at P2 matches the published P2
preference of rat chymotrypsin determined from measure-
ments of acyl transfer to pentapeptide nucleophiles (51). In
addition to the preferred Leu, some of the phage clones selected
contained Asp or Glu at the P2 position of the SGPI-2 reactive
loop (see Fig. 1B and supplemental Table S3). This finding was
unexpected, as the aforementioned acyl-transfer experiments
indicated that acidic side chains at P2 are poorly recognized by
rat chymotrypsin or rat anionic trypsin (52), but was consistent
with potentially stabilizing electrostatic interactions withArg56
and Arg162 identified in our structural model. Binding experi-
mentswith SGPI-2 variants carrying a P2Asp revealed that bind-
ing affinity to CTRCwas onlymoderately compromised (on aver-
age 3.6-fold versus Leu P2) but the P2 Asp increased the
selectivity of the inhibitorsmore significantly, particularly against
pancreatic elastases (see discussion on selectivity below).
Arguably, the most exciting observation from the present
study was the highly restricted selection of acidic Asp and Glu
amino acid residues at the P4 position of the reactive loop of
SGPI-2 variants. Binding experiments comparing inhibitors
with P4Glu versusAla demonstrated that the acidic side chain
at P4 increases binding affinity by an order of magnitude on
average. Furthermore, inspection of known regulatory cleavage
sites for human CTRC in digestive proenzymes reveals that an
acidic residue at P4 is present in all four sequences (Table 1).
Taken together, the observations strongly suggest that an inter-
action between CTRC and the P4 position of substrates and
inhibitors is a major determinant of CTRC recognition and
specificity. This property of CTRC appears unique among the
pancreatic digestive proteases, as no P4 preference has been
described for trypsin, chymotrypsin, or pancreatic elastase so
far. Interestingly, a similar but less pronounced acidic P4 pref-
erence was reported for human granzyme B, a serine protease
found in the granules of cytotoxic lymphocytes (55, 56).
In the reactive loop of natural canonical inhibitors that
inhibit pancreatic proteases the presence of an acidic Glu or
Asp at P4 is unusual, and Pro is often found here. Among the
153 ovomucoid third domains isolated by Laskowski and co-
workers (46) the P4Pro is strictly conserved. Within the 20
known members of the pacifastin family Pro occupies the P4
position in eight inhibitors (including SGPI-2), other hydro-
phobic residues (Leu, Ile, Val, or Ala) are present in seven cases,
whereas Arg is found in four members and Gln in one (32).
Examination of crystal structures of pacifastin inhibitors bound
to serine proteases reveals that in the complex between bovine
chymotrypsin and PMP-C a P4 Pro stacks against Phe39 (chy-
motrypsin numbering) of the enzyme (26). The same packing
interactionwas found between P4 Pro of SGTI and Phe39 (chy-
motrypsin numbering) of crayfish trypsin (42, 44). In the com-
plex between Fusarium oxysporum trypsin and LMPI-3 the P4
Arg participates in an H-bond with Asn37 (chymotrypsin num-
bering) of the enzyme (45). On the other hand, in the complex
of bovine chymotrypsin and a P1-P1 mutant of PMP-D2, in
which the P4 residue is Gln, there is no detectable P4-S4
interaction (26). These structural examples indicate that the
P4 position can contribute to inhibitor binding, although func-
tional studies confirming the significance of the P4-S4 inter-
actions in these complexes are lacking. We also note that the
interacting loop of SGPI-2 is flexible (41), and the P4 position,
being the penultimate residue in SGPI-2,may be conformation-
ally less constrained than in other canonical inhibitors.
To identify the amino acid residues in human CTRC that
interact with a P4 Glu/Asp side chain, we created a model of
theCTRC-C6 inhibitor complex using homologymodeling.On
the basis of this model, we then subjected three positively
charged residues (Lys51, Arg56, and Arg80) to mutagenesis and
confirmed that this cluster of basic residues on the surface of
CTRC is responsible for the observed acidic preference at P4.
Interestingly, Arg80 is not conserved in the bovine, rat, mouse,
horse, and dog CTRC, whereas pig CTRC lacks Lys51, suggest-
ing that the strong P4 Glu/Asp reference may be a distinctive
property of the human enzyme.
The SGPI-2 variants selected against CTRC exhibited not
only high binding affinity but also good selectivity against other
pancreatic chymotrypsins and elastases. In this respect, the best
inhibitor was C6, which was from 225- to 112,664-fold more
selective towardCTRC than other proteases. The highest selec-
tivity was observed against ELA3A, whereas the lowest was
against CTRL1 and ELA2A. Selectivity was determined by
amino acids at P1, P2 and P4 positions of the reactive loop. P1
Leu (versus Met) increased selectivity by an average of 4-fold.
The P2Asp (versus Leu) increased selectivity on average 7-fold
against elastases and CTRL1 but it had only a small impact on
selectivity against CTRB1 and CTRB2. Finally, themost impor-
tant determinant of selectivity was the P4 Glu amino acid res-
idue, which increased selectivity (over P4 Ala) on average by
10-fold against elastases and 55-fold against chymotrypsins.
In summary, we selected novel small protein inhibitors
against humanCTRCusing a phage display approach and iden-
tified a functionally important interaction between the acidic
P4 amino acid residue of inhibitors and a basic amino acid
cluster in CTRC. The high affinity and strong selectivity of the
inhibitors developed in the present study opens upnew avenues
for experiments on the physiological function of CTRC in
digestion and on the pathological role of CTRC mutants in the
development of chronic pancreatitis.
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Supplementary Figure S1. Expression constructs for SGPI-2. A. N-terminal fusion with the p8 coat 
protein for display on the surface of M13 phage. B. C-terminal fusion with the maltose binding protein 
(malE) for high level periplasmic expression in E. coli. See Experimental Procedures for details. MalE 
ss, maltose binding protein signal sequence; TEV site, tobacco etch virus protease cleavage site.
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 Supplementary Table S1.  Inhibition of human pancreatic chymotrypsins and elastases by 
ecotin.  Equilibrium dissociation constants (KD) were determined as described in Experimental 
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Supplementary Table S2.  Chromogenic (p-nitroanilide, pNA) and fluorogenic (7-amino-4-
methyl coumarin, AMC) peptide substrates used to measure residual enzyme activity in the 
equilibrium binding assay.  The concentrations indicated are the final concentrations in the assay 
mix. 
 
enzyme substrate concentration(µM) KM (µM) 
CTRC Suc-AAPF-AMC 150 35.0 
CTRB1 Suc-AAPF-AMC 150 255.5 
CTRB2 Suc-AAPF-AMC 150 39.7 
CTRL1 Suc-AAPF-AMC 150 102.1 
ELA2A Suc-AAPL-pNA 150 999.5 
ELA3A Suc-AAPA-pNA 1500 2435.2 
ELA3B Suc-AAPA-pNA 150 785.1 
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 Supplementary Table S3.  Amino-acid sequence of the reactive loop of SGPI-2 variants 
selected by phage display.   These 22 clones differed at the DNA sequence level, indicating 
independent selection. 
 
P4  P3  P2  P1  P1' P2' P3' P4' 
A   C   T   M   M   L   C   Y 
G   C   T   M   M   W   C   D 
Y   C   T   M   M   Y   C   D 
Y   C   S   L   M   E   C   E 
A   C   S   L   M   L   C   E 
A   C   S   L   L   D   C   E 
A   C   T   M   M   L   C   E 
A   C   T   M   M   L   C   E 
A   C   T   M   M   L   C   D 
G   C   T   M   L   L   C   E 
M   C   T   M   L   L   C   E 
H   C   T   L   L   L   C   D 
G   C   T   F   L   L   C   E 
A   C   T   L   L   M   C   D 
S   C   T   L   A   L   C   D 
S   C   T   L   A   L   C   E 
G   C   T   Y   K   L   C   D 
G   C   T   L   M   V   C   D 
L   C   T   L   M   L   C   E 
L   C   T   L   M   L   C   E 
V   C   T   L   M   L   C   D 
G   C   T   M   M   L   C   E 
 
 at Boston University M









 Supplementary Table S4.  Kinetic parameters of CTRC mutants on the Suc-Ala-Ala-Pro-Phe-p-












 kcat (s-1) KM (µM) kcat/KM (M-1·s-1) 
CTRC 14.9 21.2 7.0×105 
K51A 16.7 16.5 1.0×106 
R56A 15.3 18.8 8.1×105 
K51A,R56A 14.2 15.3 9.3×105 
R80L 12.4 26.1 4.8×105 
R56E 9.6 14.0 6.9×105 
 at Boston University M









 Supplementary Table S5.  Inhibition of CTRC mutants by wild-type SGPI-2 chymotrypsin 
inhibitor.  Equilibrium dissociation constants (KD) were determined as described in Experimental 
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